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Rett syndrome (RTT) is a neurodevelopmental disor-
der caused byMECP2mutations. Although emerging
evidence suggests that MeCP2 deficiency is associ-
ated with dysregulation of mechanistic target of
rapamycin (mTOR), which functions as a hub for
various signaling pathways, the mechanism underly-
ing this association and the molecular pathophysi-
ology of RTT remain elusive. We show here that
MeCP2 promotes the posttranscriptional processing
of particular microRNAs (miRNAs) as a component of
the microprocessor Drosha complex. Among the
MeCP2-regulated miRNAs, we found that miR-199a
positively controls mTOR signaling by targeting
inhibitors for mTOR signaling. miR-199a and its tar-
gets have opposite effects onmTOR activity, amelio-
rating and inducing RTT neuronal phenotypes,
respectively. Furthermore, genetic deletion of miR-
199a-2 led to a reduction of mTOR activity in the
brain and recapitulated numerous RTT phenotypes
in mice. Together, these findings establish miR-
199a as a critical downstream target of MeCP2 in
RTT pathogenesis by linking MeCP2 with mTOR
signaling.Cell RepINTRODUCTION
Rett syndrome (RTT) is a severe progressive neurodevelopmen-
tal disorder that affects approximately one in 10,000 females.
Afflicted individuals appear to develop normally for the first
6–18 months but then regress, with the onset of various neuro-
logical symptoms including impaired motor function, mental
retardation, seizure, autistic features, and stereotyped behaviors
(Bienvenu and Chelly, 2006). RTT is predominantly caused by
mutations in the X-linked gene encoding methyl-CpG binding
protein 2 (MeCP2) (Amir et al., 1999). Mutations in MECP2 are
also associated with other neurodevelopmental diseases
including psychiatric disorders, cognitive disorders, and some
cases of autism (Cohen et al., 2002; Klauck et al., 2002; Lam
et al., 2000; Orrico et al., 2000).
MeCP2 was originally identified as a methylated-DNA-binding
transcriptional repressor (Jones et al., 1998; Nan et al., 1997).
MeCP2 induces repression of gene expression by recruiting a
corepressor complex (Harikrishnan et al., 2005; Jones et al.,
1998). However, MeCP2 is becoming recognized as a pleiotropic
protein, which can also mediate transcriptional activation and
mRNA splicing (Chahrour et al., 2008; Young et al., 2005).
Although MeCP2-deficient neurons clearly underlie the RTT
phenotype, other studies have shown that the loss of MeCP2
in glia negatively influences normal neuronal functions in a
non-cell-autonomous fashion in vitro and in vivo (Ballas et al.,
2009; Lioy et al., 2011; Maezawa and Jin, 2010).orts 12, 1887–1901, September 22, 2015 ª2015 The Authors 1887
Several mousemodels of RTT have been reported (Chen et al.,
2001; Guy et al., 2001; Shahbazian et al., 2002). These models
recapitulate many characteristic features of RTT, including the
delayed-onset neurological phenotype and early mortality. Con-
ditional deletion ofMeCP2 in the brain causes symptoms that are
indistinguishable from those observed in conventional MeCP2-
knockout (KO) mice. Moreover, re-expression of MeCP2 in the
MeCP2-deficient brain is sufficient to prevent the onset of the
neurological phenotype (Guy et al., 2007; Luikenhuis et al.,
2004).
In addition to genetic studies, several lines of evidence further
support the effects of MeCP2 dysfunction on neuronal proper-
ties in RTT patients and model mice. Although both exhibit pro-
found neurological abnormalities, the major neuropathological
changes in the CNS are characterized by smaller neuronal
soma and an overall decrease of brain size (Armstrong, 2005;
Bauman et al., 1995; Chahrour and Zoghbi, 2007; Chen et al.,
2001; Kaufmann et al., 2000). Subtle alterations of neuronal den-
sity, dendritic arborization, and spine formation in some specific
brain regions and stages are also found in both patients and
model mice in which MeCP2 is mutated (Armstrong, 2005; Beli-
chenko et al., 1994; Chapleau et al., 2009; Landi et al., 2011). It
has been proposed that synaptic alterations constitute a major
substrate of the disease symptoms (Boggio et al., 2010; Zoghbi,
2003). Neurophysiological studies of RTT patients and model
mice have revealed alterations in excitatory synaptic functions
(Asaka et al., 2006; Dani et al., 2005; Glaze, 2005). In particular,
synaptic properties of MeCP2-deficient neurons are well studied
in in vitro culture systems. Primary cultured hippocampal neu-
rons from MeCP2-KO mice show a decrease in the frequency
of spontaneous excitatory synaptic transmission (Nelson et al.,
2006), and loss and overexpression of MeCP2 have opposite
effects, respectively decreasing and increasing the number of
excitatory synapses in individual neurons (Chao et al., 2007).
The molecular mechanisms underlying these morphological
and physiological alterations are unknown.
The mechanistic target of rapamycin (mTOR) protein kinase
acts as a critical sensor/integrator of diverse environmental sig-
nals that are converted to neuronal activity and synaptic inputs.
mTOR function is mediated through two distinct complexes,
mTOR complex 1 (mTORC1) andmTORC2. mTORC1 phosphor-
ylates a range of substrates to control major cell processes such
asmRNA translation, lipid synthesis, and autophagy. mTORC2 is
implicated in the activation of Akt and in the regulation of the
cytoskeleton (Laplante and Sabatini, 2012; Shimobayashi and
Hall, 2014). The evolutionarily conserved mTOR signaling
pathway has been shown to play a critical role as a key determi-
nant of cellular size (Lloyd, 2013). Further crucial roles of mTOR
signaling in brain functions are highlighted by the fact that muta-
tions of genes in the mTOR signaling pathway occur in various
neurological diseases such as neurodevelopmental and psychi-
atric disorders (Costa-Mattioli and Monteggia, 2013).
The most distinctive phenotypes caused by MeCP2 defi-
ciency, i.e., smaller neuronal soma and an overall decrease of
brain size, offer a clue to unveil RTT molecular pathology. As
described above, because mTOR signaling is a critical regulator
of cell/tissue size, it has been assumed that mTOR signaling is
involved in RTT pathogenesis. In support of this hypothesis,1888 Cell Reports 12, 1887–1901, September 22, 2015 ª2015 The AMeCP2-KO brain and MeCP2-mutated human neurons were
recently reported to exhibit reduced activation of the mTOR
signaling pathway (Li et al., 2013; Ricciardi et al., 2011). Further-
more, several works suggest that the activation of mTOR
ameliorates abnormal phenotypes in MeCP2 mutant mice, RTT
patient-derived neurons, and human embryonic stem (ES) cell-
derived neurons withMECP2mutation (Li et al., 2013; Marchetto
et al., 2010; Tropea et al., 2009). This raises the possibility that
mTOR plays a crucial role downstream of MeCP2, which may
be a key to elucidate the molecular basis of RTT pathogenesis.
Nevertheless, the molecular mechanism linking MeCP2 function
and mTOR signaling is obscure.
In this study, we found that MeCP2 associates with the micro-
RNA microprocessor Drosha complex and identified miR-199a
as an mTOR-regulating downstream target of the MeCP2-
Drosha complex. We further demonstrated that genetic deletion
of miR-199a-2 led to a reduction of mTOR activity in the brain
and recapitulated numerous RTT phenotypes in mice. These
findings therefore suggest that MeCP2/miR-199a/mTOR axis
contribute to RTT pathophysiology.
RESULTS
MeCP2 Associates with miRNA Microprocessor Drosha
Complex
To obtain a clue to elucidate the molecular mechanism that un-
derlies RTT pathogenesis and links MeCP2 to the mTOR
signaling pathway, we performed comprehensive proteomic
screening of mouse brain cells to identify protein partners of
MeCP2 in highly enriched populations of the four major CNS
cell types: neural stem cells (NSCs), neurons, astrocytes, and
oligodendrocytes (Figure S1A). We then categorized the
MeCP2-interacting candidate molecules in each cell type ac-
cording to the GeneOntology (GO) biological processes in which
they are involved (Figure 1A). Because MeCP2 is a well-known
transcriptional repressor/activator, it was expected that tran-
scription-related molecules would appear among the MeCP2 in-
teractors; surprisingly, however, we also observed numerous
members of other functional categories such as nucleosome as-
sembly, translation, and RNA processing (Figure 1A). Strikingly,
five components of the miRNA microprocessor Drosha complex
(Gregory et al., 2004)—the DEAD-box RNA helicases DDX5 and
DDX17, and heterogeneous nuclear ribonucleoproteins G/M/U
(hnRNPG/M/U)—were common to at least three or all four of
the CNS cell types (Figures 1B and 1C). These same Drosha
complex components were also detected, by LC-MS/MS, in
endogenous MeCP2 complexes obtained from postnatal day
(P)1mouse brains (Figure 1D). These findings prompted us to as-
sume that MeCP2 plays hitherto-unknown roles in miRNA
processing.
The miRNA microprocessor Drosha complex consists of Dro-
sha,DiGeorgesyndromecritical regiongene8 (DGCR8), andmul-
tiple classes of RNA-associated proteins, including DDX5 and
DDX17, that are required for the processing of some, but not all,
miRNAs (Gregory et al., 2004). The appearance of Drosha com-
plex proteins among MeCP2 co-immunoprecipitates prompted
us to examine whether MeCP2 might function unexpectedly as
a facilitator of miRNA processing.uthors
Figure 1. MeCP2 Associates with the Microprocessor Drosha Complex
(A) Pie charts representing MeCP2 interactors identified in each CNS cell type. Proteins identified in either or both MeCP2a and MeCP2b immunoprecipitates
were considered as MeCP2 binding partners and are categorized.
(B) Venn diagram of common MeCP2-binding proteins identified in the four CNS cell types.
(C) Components of the Drosha complex identified bymass spectrometry asMeCP2-binding proteins. Cell types in which each protein was identified are indicated
in the rightmost column. M, molecular mass.
(D) Validation of MeCP2 protein partners identified in the proteomic screen by LC-MS/MS analysis of the immunoprecipitate (using anti-MeCP2 antibody) fromP1
mouse brain lysate. Components of the Drosha complex are indicated in red. Molecular masses of marker proteins are indicated. M, molecular mass.
(E and F) Immunoprecipitation assays were performed to examine the association between exogenous or endogenous MeCP2 and components of the Drosha
complex in HEK293T cells (E) and P2 mouse brain (F).
IB, immunoblot; I.P., immunoprecipitation.We first investigated molecular interactions between MeCP2
and components of the Drosha complex. Exogenous MeCP2
associated with DDX5 and Drosha in human HEK293T cells (Fig-
ure 1E). Using a reciprocal co-immunoprecipitation assay, we
also confirmed that endogenous MeCP2 associated with coreCell Repcomponents of the Drosha complex including Drosha, DGCR8,
and DDX5 in a mouse brain lysate (Figure 1F). Biochemical anal-
ysis also revealed that exogenous and endogenous MeCP2
complex contains the components of Drosha complex (Figures
S1B–S1D). These results indicate that MeCP2 associates withorts 12, 1887–1901, September 22, 2015 ª2015 The Authors 1889
(legend on next page)
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the core components of the Drosha complex, both in vitro and
in vivo.
Recent work has reported that MeCP2 interferes with the as-
sociation of Drosha with DGCR8 in the Drosha complex (Cheng
et al., 2014). However, we did not find any significant change in
the association between Drosha and DGCR8 regardless of
MeCP2 expression level (Figures S1E–S1H).
MeCP2 Regulates Processing of a Specific miRNA
To identify target miRNAs of the MeCP2-Drosha complex, we
performed deep RNA sequencing using a small non-coding
RNA fraction extracted from neurons and NSCs of wild-type
(WT) andKOmice. No drastic and/or overall alterations ofmature
miRNA expression levels were observed in either cell type (Fig-
ures 2A and 2B), suggesting that MeCP2 does not affect core
Drosha-DGCR8 microprocessor function. We then searched
for miRNAs whose level decreased over 1.5-fold in MeCP2-KO
cells compared with WT. Sixty and 75 miRNAs were reduced
inMeCP2-KO neurons andNSCs, respectively (Figure 2C). Since
MeCP2 associates with the Drosha complex in both cell types,
we focused on miRNAs that decreased in both cell types and
found nine that met this criterion.
We then performed functional screening for mTOR signal-
regulating miRNAs that act downstream of MeCP2. We ex-
pressed the ninemiRNAs in hippocampal neurons and evaluated
neuronal soma size, since mTOR signaling is known to regulate
cellular soma size, and found that only miR-199a increased the
neuronal soma size to a similar extent as MeCP2 expression
did (Figure 2D). We also found that miR-199a expression and
blockade (see below for details) potentiated and attenuated,
respectively, the phosphorylation levels in neurons of S6 ribo-
somal protein, which signify the activation of mTOR signaling,
indicating thatmiR-199a positively regulatesmTOR signaling ac-
tivity (Figures S2A and S2B). Therefore, we decided to focus on
miR-199a in the following experiments.
miR-199a is expressed from two genomic loci, miR-199a-1
and miR-199a-2, and pri-miR-199a-2 is synthesized with pri-
miR-214 as a single transcript (Lee et al., 2009). Two types of
mature form, miR-199a-5p and -3p, are generated from both
miR-199a-1 and miR-199a-2 (Figure S2C), but no function of
miR-199a in the nervous systemhas yet been reported. To deter-
mine whether MeCP2 specifically regulates posttranscriptionalFigure 2. MeCP2 Regulates Posttranscriptional Processing of a Speci
(A and B) Scatterplot of miRNA expression levels (log10) in neurons (A) or NSCs
(C) Venn diagram showing the overlap of miRNAs whose levels are lower in MeCP
overlap in the two cell types.
(D) Functional screening for mTOR signaling-related miRNA that acts downstrea
campal neurons and neuronal soma size was evaluated. (*p < 0.05 compared to
and -GFP (green) antibodies. P0WT hippocampus-derived neuronswere infected
primary-miR-199a and cultured for 10 days. Scale bar, 10 mm (left). Quantitative
(E and F) Expression levels of mature (E) and primary (F) forms of the indicatedmiR
analysis (*p < 0.05 compared to WT; n.s., not significantly different; n = 3).
(G and H) Expression levels of mature (G) and primary (H) forms of the indicate
MeCP2-expressing lentiviruses by qRT-PCR analysis (*p < 0.05 compared to co
(I) Exogenous MeCP2 expressed by a recombinant lentivirus could restore the miR
in WT hippocampal neurons (*p < 0.05 compared to WT; n.s., not significantly d
(J) RIP analysis of the association of pri-miR-199a-1 and pri-miR-199a-2 with M
control IgG and anti-MeCP2 antibody (*p < 0.05 compared to IgG; n = 3).
Cell Repprocessing of miR-199a, we first measured the expression levels
of primary and mature forms of miR-199a and miR-214, by qRT-
PCR, in hippocampal neurons from WT and MeCP2-KO mice.
We found that the mature forms miR-199a-5p and miR-199a-
3p were downregulated in MeCP2-KO neurons (Figure 2E); the
same held true in MeCP2-KO NSCs (Figure S2D), as reported
previously (Szulwach et al., 2010). In contrast, pri-miR-199a-1
and -2 levels showed no significant change in MeCP2-KO neu-
rons compared with those inWT neurons (Figure 2F), suggesting
that the reduced mature-form levels were not caused by
decreased levels of transcription. In addition, expression levels
of the mature forms of miR-214 and miR-137, the latter previ-
ously identified as a transcriptional repression target of MeCP2
in NSCs (Szulwach et al., 2010), were unchanged (Figures 2E
and 2F; Figures S2D and S2E). Conversely, overexpression of
MeCP2 in WT neurons led to significant increases of mature
miR-199a-5p and -3p but not of mature miR-214 (Figure 2G).
Expression of primary miR-199a and miR-214 was either un-
changed or slightly reduced in response to MeCP2 overexpres-
sion in WT neurons (Figure 2H). To further determine whether
MeCP2 regulates the expression of miR-199a, we also re-ex-
pressed MeCP2 in MeCP2-KO neurons. As expected, this
restored the level of mature-miR-199a expression to that in WT
neurons (Figure 2I). No change in thematuremiR-137 expression
level was observed (Figure S2E). Together, these results suggest
that MeCP2 modulates specifically the posttranscriptional pro-
cessing of pri-miR-199a, rather than its transcription. Dysregula-
tion of miR-199a expression at posttranscriptional level was also
observed in the frontal cortex of RTT patients (Table S1; Figures
S2F and S2G), suggesting that the reduction of miR-199a
expression may associate with RTT pathophysiology.
We then examined the in vivo association of pri-miR-199a with
the MeCP2 complex by RNA immunoprecipitation assay and
found that both pri-miR-199a-1 and pri-miR-199a-2 clearly
associated with the complex (Figure 2J). We also performed an
in vitro pri-miRNA processing assay by incubating radiolabeled
pri-miR-199a-2 substrate with anti-FLAG antibody immunopre-
cipitates from Neuro2A cells transfected with empty vector
(mock), or with FLAG-tagged MeCP2- or FLAG-tagged Dro-
sha-expressing constructs. pri-miR-199a-2 processing activity
in the MeCP2 complex immunoprecipitates was comparable to
that in Drosha complex immunoprecipitates, and higher thanfic miRNA
(B) from WT and MeCP2-KO, respectively.
2-KO neurons and NSCs than in WT. Nine miRNAs, listed below the diagram,
m of MeCP2. The nine miRNAs identified in (C) were expressed in WT hippo-
control; n = 3). Representative images of neurons stained with anti-MAP2 (red)
with lentiviruses expressingGFP alone (control) or GFP together withMeCP2 or
analysis of the functional screening (right).
NAs were examined inWT andMeCP2-KO hippocampal neurons by qRT-PCR
d miRNAs were examined in hippocampal neurons infected with control and
ntrol; n.s., not significantly different; n = 3).
-199a-5p expression levels in MeCP2-KO hippocampal neurons to those seen
ifferent; n = 3).
eCP2 in P1 hippocampal neurons. Immunoprecipitation was performed using
orts 12, 1887–1901, September 22, 2015 ª2015 The Authors 1891
Figure 3. miR-199a Overcomes Neuronal Abnormalities Caused by the Loss of MeCP2 and Acts Downstream of MeCP2
(A) Representative traces of individual mEPSC frequency recordings. P0–P2WT andMeCP2-KOhippocampal neuronswere infectedwith lentiviruses expressing
GFP alone (control) or GFP together with the precursor form of miR-199a and cultured for 10–14 days.
(B) Quantification of mEPSC frequency and amplitude in (A). The number of neurons analyzed is shown under each bar.
(C) Representative images of cultured hippocampal neurons as indicated, stained with antibodies against VGLUT1 (green), PSD-95 (red), and MAP2 (blue).
Scale bar, 5 mm.
(D) Normalized densities of colocalized VGLUT1 and PSD-95 signal in the hippocampal cultures in (C) were quantified (n = 10 neurons per group).
(E) Quantification of neuronal soma size relative to control WT neurons. n = 3 independent experiments; in each experiment at least 100 neurons were assessed.
(F) Representative traces of individual mEPSC frequency recordings of WT hippocampal neurons co-infected with control or MeCP2-expressing lentiviruses and
those expressing sponge miRNA inhibitors against either miR-199a-5p or miR-199a-3p.
(G) Quantification of mEPSC frequency and amplitude in (F). The number of neurons analyzed is shown under the bars.
(H) Representative images of cultured hippocampal neurons as indicated, stained with antibodies against VGLUT1 (green), PSD-95 (red), and MAP2 (blue).
Scale bar, 5 mm.
(legend continued on next page)
1892 Cell Reports 12, 1887–1901, September 22, 2015 ª2015 The Authors
that in immunoprecipitates frommock-transfected cells (Figures
S2H and S2I). Moreover, Drosha complex from MeCP2-knock-
down cells showed lower processing activity against pri-miR-
199a than that from control cells (Figures S2J and S2K). In
contrast, processing activity by the Drosha immunoprecipitates
against pri-miR-214 was similar regardless of MeCP2 expres-
sion levels. Taken together, these results indicate that MeCP2
specifically contributes to the posttranscriptional processing of
pri-miR-199a.
miR-199a Acts Downstream of MeCP2 In Vitro and
In Vivo
MeCP2 target molecules that can rescue major RTT neuronal
phenotypes such as decreased excitatory synaptic transmis-
sion, synaptic density, and soma size have not been identified.
Therefore, we investigated whether miR-199a, identified here
as a MeCP2 target, restores RTT neuronal properties of
MeCP2-deficient neurons.
MeCP2-KO neurons displayed a significantly lower miniature
excitatory postsynaptic current (mEPSC) frequency, lower syn-
aptic density, and smaller soma size than WT neurons, as re-
ported previously (Chao et al., 2007; Nelson et al., 2006) (Figures
3A–3E). These impairments were overcome by the re-introduc-
tion of MeCP2 (Figures S3A–S3E). Likewise, expression of
precursor form miR-199a in MeCP2-KO neurons completely
restored RTT neuronal phenotypes such as decreased mEPSC
frequency, excitatory synaptic density, and soma size, indicating
that miR-199a can substitute for the function of MeCP2 in neu-
rons (Figures 3A–3E; Figures S3F and S3G). No significant differ-
ences in mEPSC amplitude were observed under any conditions
(Figures 3A–3E).
To determine whether miR-199a indeed acts downstream of
MeCP2, we inhibited miR-199a function in MeCP2-overexpress-
ing WT hippocampal neurons using miRNA inhibitors against
miR-199a-5p or miR-199a-3p. The increase of mEPSC fre-
quency and synaptic density as well as the enlargement of
neuronal soma size induced by MeCP2 overexpression were
abolished when the cells were treated with miR-199a-5p inhibi-
tor but not with control or miR-199a-3p inhibitor (Figures 3F–
3J). Although miR-134 was reported to act downstream of
MeCP2 (Cheng et al., 2014), the expression of miR-134 in neu-
rons did not influence the effects of MeCP2 overexpression in
our experimental setting (Figures S3H–S3L).
To test whether blocking endogenous activities of miR-199a
recapitulates the RTT neuronal phenotype, we treated WT hip-
pocampal neurons with miRNA inhibitors against miR-199a-5p
or miR-199a-3p. In contrast to scrambled control and miR-
199a-3p inhibitor, treatment with an inhibitor of miR-199a-5p re-
sulted in a significant reduction of mEPSC frequency, synaptic
density, and soma size (Figures S3M–S3Q). We also observed
that overexpression of miR-199a in WT hippocampal neurons
phenocopied MeCP2 overexpression (Figures S3R–S3V). We
further demonstrated that inhibition of endogenous miR-214(I) Normalized densities of colocalized VGLUT1 and PSD-95 signals in the hippo
(J) Quantification of neuronal soma size relative to control WT neurons. n = 3 inde
(K) Models of the regulation of miRNA processing by the MeCP2-Drosha comple
represented as mean ± SEM. *p < 0.05.
Cell Repand expression of miR-214 could not abolish the effect of
MeCP2 expression (mEPSC) (Figures S3W and S3X) and could
not restore the RTT neuronal phenotypes (synaptic density and
soma size) (Figures S3Y and S3Z), respectively. When we per-
formed in utero electroporation to mouse embryonic brains,
the effects of MeCP2 and miR-199a on soma size observed
in vitro could be reproduced in vivo (data not shown). These re-
sults strongly indicate that miR-199a, specifically miR-199a-5p,
is a direct MeCP2 target that critically contributes to MeCP2
functions (Figure 3K).
miR-199a Targets Inhibitory Factors of the mTOR
Signaling Pathway
To identify target genes downstream of miR-199a that are phys-
iologically relevant to RTT pathogenesis, we searched for mTOR
signal-inhibiting genes that have miR-199a-5p target sequences
in their 30 UTRs using public databases including TargetScan
5.1, miRDB, Pictor, and miRanda. This search yielded three
candidate genes: Pde4d, Sirt1, and Hif1a (Ghosh et al., 2010;
Kim et al., 2010; Wouters and Koritzinsky, 2008) (Figure 4A). To
examine whether these genes are actual targets of miR-199a,
we conducted luciferase assays using reporter constructs
harboring 30 UTR of each gene, within which were native or
mutated sequence complementary to the miR-199a seed
sequence, in hippocampal neurons. The luciferase activities of
native Pde4d, Sirt1, and Hif1a-30 UTR constructs were all
reduced significantly by miR-199a expression, whereas those
of mutated Pde4d, Sirt1, and Hif1a-30 UTR constructs were un-
affected (Figure 4B). We then examined protein levels of PDE4D,
SIRT1, and HIF1a in MeCP2-KO brain and found that they were
indeed upregulated compared to those in WT (Figures 4C and
4D), suggesting that miR-199a targets Pde4d, Sirt1, and Hif1a
downstream of MeCP2 and downregulates their cognate protein
levels.
Having suggested that MeCP2 and miR-199a are epistatic to
and negatively regulate PDE4D, SIRT1, and HIF1a, we tested
whether expression of thesemTOR signal negative regulators re-
verses the effect of MeCP2 expression in neurons. Because
HIF1a is degraded through hydroxylation of specific proline res-
idues in a normal atmosphere, we used in this experiment a
constitutively active form of HIF1a (HIF1a-CA) whose hydroxyl-
ation-targeted proline residues are substituted by alanine (Jaak-
kola et al., 2001). The expression of Pde4d, Sirt1, and Hif1a
(without their cognate 30 UTR) abolished the enhanced mEPSC
frequency, the increase in synapse number, and the enlarged
soma size induced by MeCP2 overexpression (Figures 4E–4S).
Interestingly, Pde4d, Sirt1, and Hif1a-CA with their native
30 UTR sequences failed to abolish these effects of MeCP2 over-
expression, while constructs with a 30 UTR harboring a mutation
in the miR-199a-target sequence significantly attenuated the
effects of MeCP2 (Figures 4E–4S), indicating that miR-199a
plays a critical role in controlling the expression of these mTOR
signal inhibitors.campal cultures in (H) were quantified (n = 10 neurons per group).
pendent experiments; in each experiment at least 100 neurons were assessed.
x in normal and RTT cells, and of the resultant neuronal phenotypes. Data are
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Figure 4. Three Negative Regulators of mTOR Signaling Are Functional Downstream Targets of miR-199a
(A and B) Luciferase reporter assays of the predictedmiR-199a target genes. Schematics of luciferase assay reporter constructs are shown in (A). The miR-199a-
5p seed sequence, miR-199a-5p target (upper, Nat), and its mutated (lower, Mut) sequences of each gene’s 30 UTR is indicated (blue boxes). The mir-199a-5p
seed and its target sequences in Pde4d, Sirt1, and Hif1a 30 UTRs are highlighted in light blue. Reduction of luciferase activity of Pde4d, Sirt1, and Hif1a 30 UTRs
with native miR-199a-5p sequences was observed (B). Data are represented as mean ± SEM. *p < 0.05. n = 3 independent experiments.
(C) Western blot analysis showing that protein levels of PDE4D, SIRT1, and HIF1a are upregulated in MeCP2-KO brain (P1 cortex).
(D) Quantification of protein levels of PDE4D, SIRT1, and HIF1a. n = 3 brains from each genotype.
(E–S) PDE4D, SIRT1, and HIF1a act downstream of MeCP2/miR-199a.
(legend continued on next page)
1894 Cell Reports 12, 1887–1901, September 22, 2015 ª2015 The Authors
We next asked whether the inhibition of these miR-199a
downstream targets ameliorated RTT neuronal phenotypes.
When we pharmacologically inhibited PDE4D with rolipram and
SIRT1 with nicotinamide (NIC) and EX527, the defects in
mEPSC, synaptic density, and soma size of MeCP2-KO neurons
were all overcome (Figures S4A–S4O). Knockdown of Pde4d
also remarkably restored these RTT neuronal phenotypes (Fig-
ures S4P–S4T). In addition, treatment with rolipram, NIC, and
EX527 significantly recovered the neuronal impairments induced
by the inhibition of miR-199a-5p (Figures S4U–S4D0). Moreover,
when PDE4D, SIRT1, and HIF1a-CA were expressed in WT hip-
pocampal neurons, similar neuronal impairments to those
caused by MeCP2 deficiency and miR-199a inhibition were
observed (Figures S4E0–S4J0). Taken together, these data sup-
port our model that Pde4d, Sirt1, and Hif1a are functional down-
stream targets of miR-199a in RTT neuropathology.
mTOR Underlies MeCP2-Related RTT Neuronal
Phenotypes
Although the mTOR signaling pathway is dysregulated in
MeCP2-deficient mice and cells (Li et al., 2013; Ricciardi et al.,
2011), it has not been ascertained that mTOR signaling indeed
functions downstream of MeCP2. Therefore, we first investi-
gated whether activation of mTOR signaling ameliorates RTT
neuronal phenotypes. We found that expression of Rheb, an up-
stream activator of mTOR, in MeCP2-KO hippocampal neurons
clearly restored the neuronal impairments observed in MeCP2-
KO neurons affecting mEPSC, synaptic density, and soma size
(Figures 5A–5E). Moreover, activation of mTOR signaling by
Rheb expression reversed the defects in neurons induced by
miR-199a-5p inhibition and by PDE4D, SIRT1, and HIF1a-CA
expression (Figures 5F–5J; Figures S5A–S5O). In support of
these results, inhibition of mTOR by rapamycin strikingly abro-
gated the effects induced by MeCP2 and miR-199a expression,
and by the pharmacological inhibition of miR-199a targets
(PDE4D with rolipram and SIRT1 with EX527) (Figures 5K–5T;
Figures S5P–S5Y). Furthermore, activation and inhibition of
mTOR signaling in WT hippocampal neurons recapitulated the
gain and loss of MeCP2 phenotypes, respectively (Figures
S5Z–S5I0). Collectively, these findings demonstrate that mTOR
signaling underlies MeCP2-related RTT phenotypes in neurons
(Figures 5U and 5V).
Loss ofmiR-199a-2 Recapitulates RTT Phenotypes
In Vivo
miR-199a-1 KO mice had already been produced and do not
display any gross physical or behavioral abnormalities (informa-(E–I) Expression of PDE4D attenuates the effect ofMeCP2 expression. Expression
of excitatory synapses (G and H), and enlargement of soma area (I) in MeCP2-ex
(J–N) Expression of SIRT1 abolishes the effect of MeCP2 expression. Expression o
excitatory synapses (L and M), and enlargement of soma area (N) in MeCP2-exp
(O–S) Expression of HIF1a-CA attenuates the effect of MeCP2 expression. Expres
number of excitatory synapses (Q and R), and enlargement of soma area (S) in M
vector containing each native 30 UTR (PDE4D-30 UTR Nat, SIRT1-30 UTR Nat, and
contrast, the Pde4d, Sirt1, and Hif1a expression vector containing each mutated
efficiently abrogated the effects ofMeCP2. Data are represented asmean ±SEM.
5 mm. Regarding quantification of neuronal soma size, n = 3 independent experi
Cell Reption from The Jackson Laboratory: http://jaxmice.jax.org/strain/
017512.html) (Park et al., 2012), and it has been reported that
the Dnm3os KO mice, which lack both miR-199a-2 and miR-
214, show similar skeletal abnormality and growth retardation
to Rett patients and MeCP2 KO mice (O’Connor et al., 2009;
Watanabe et al., 2008). In contrast, miR-214 single KO
mice develop normally (Aurora et al., 2012), clearly indicating
that the phenotypes observed in Dnm3os KO mice are
attributable to the lack of miR-199a-2. Based on these obser-
vations, we further investigated the functions of miR-199a by
establishing miR-199a-2 KO mice using conventional method
(Figures S6A–S6C). To our surprise, miR-199a-2 KO mice dis-
played many RTT features that were similar to MeCP2 KO
mice (Chen et al., 2001; Guy et al., 2001). We observed a
marked reduction in size and body weight of the miR-199a-2
KO mice compared to WT littermates, while miR-199a-2-/+ het-
erozygotes are almost indistinguishable from WT (Figures 6A,
6B, and 6D). Brain size was also smaller in miR-199a-2 KO
mice (Figure 6C). Although most miR-199a-2 KO mice ap-
peared normal for the first 3 postnatal weeks, but they then
developed abnormal behavior, such as a stiff, uncoordinated
gait, body trembling, pilar erection, irregular breathing, and hy-
poactivity (Figure 6E), and began to die at around 6 weeks (Guy
et al., 2007). Immunohistochemical analysis revealed that miR-
199a-2 KO mice had normal brain architecture (Figures 6F and
6G), whereas their hippocampal and cortical neurons exhibited
a smaller cell body and nucleus (Figures 6H–6K) regardless of
MeCP2 expression (Figure S6D). In addition, we found that
these neurons in miR-199a-2 KO mice were more densely
packed than those in WT, consistent with findings in RTT
patients and MeCP2 KO mice (Figures 6H–6K) (Bauman
et al., 1995; Chen et al., 2001; Guy et al., 2001). Taken together,
these results indicate that miR-199a is a critical downstream
target of MeCP2 for RTT phenotypes in vivo.
Loss ofmiR-199a-2 Results in DecreasedmTORActivity
in the Brain
To ask whether miR-199a regulates mTOR signaling in the
brain, we assessed mTOR activity in the WT and miR-199a-2
KO brain. Concordant with our hypothesis that miR-199a
positively regulates mTOR activity, immunohistochemical anal-
ysis showed a striking reduction of pS6-positive neurons in
the cortex and hippocampus of miR-199a-2 KO mice (Fig-
ure 7). Collectively, these data suggest that miR-199a acti-
vates mTOR activity in vivo and that the MeCP2/miR-
199a/mTOR axis makes a substantial contribution to RTT
pathophysiology.of PDE4D abrogates enhancedmEPSC frequency (E and F), increased number
pressing neurons.
f SIRT1 abrogates enhancedmEPSC frequency (J and K), increased number of
ressing neurons.
sion of HIF1a-CA abrogates enhancedmEPSC frequency (O and P), increased
eCP2-expressing neurons. Note that the Pde4d, Sirt1, and Hif1a expression
HIF1a CA-30 UTR Nat) was not effective in attenuating the effects of MeCP2. In
30 UTR (PDE4D-30 UTR Mut, SIRT1-30 UTR Mut, and HIF1a CA-30 UTR Mut)
*p < 0.05. The number of neurons analyzed is shown under the bars. Scale bars,
ments; in each experiment, at least 100 neurons were assessed.
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DISCUSSION
In this study, we demonstrated that MeCP2 facilitates specific
miRNA processing as a component of Drosha complex and
identified miR-199a as a direct MeCP2 target. We also revealed
that exogenous miR-199a could overcome several impairments
in MeCP2-KO neurons, and that inhibition of endogenous miR-
199a abolished the effect of MeCP2 overexpression. Taken
together, these results provide strong evidence that miR-199a
is a direct MeCP2 target underlying the RTT phenotype. It
has been reported recently that the interaction between
Drosha and DGCR8 was attenuated in the brain lysate of
MeCP2-overexpresing transgenic mice due to the competition
of MeCP2 with Drosha for binding to DGCR8, suggesting
MeCP2 has a negative role in miRNA processing. However, in
our experimental setting using embryonic hippocampal neu-
rons, overexpression of MeCP2 did not interfere with associa-
tion of Drosha with DGCR8 and enhanced the specific miRNA
processing (Figures S5C and S5D; Figure 2G). Although
currently we do not have specific explanation of how MeCP2
exerts these opposite functions in miRNA processing, it could
be, e.g., because of that posttranslational modification status
of MeCP2 is different among different brain regions and
neuronal subtypes, since phosphorylation of MeCP2 is known
to alter MeCP2 functions (Tao et al., 2009). To verify the molec-
ular mechanism is also an important challenge for future
studies.
In the present study, we demonstrated that MeCP2 associ-
ates with pri-miR-199a-1 and pri-miR-199a-2. Nevertheless,
how MeCP2 recognizes its target miRNAs remains elusive.
Since pri-miR-199a-1 and pri-miR-199a-2 have exactly the
same sequence in their mature miRNA regions but are
completely different on the outsides, it is tempting to specu-
late that mature miRNA sequence is responsible for defining
the specificity of MeCP2. In this relation, it has been indi-
cated that transcription factor Smad1 directly binds to the
cognate sequence within the mature sequence of target
primary miRNA (Davis et al., 2010). However, precise
consensus sequence of MeCP2 binding has not so farFigure 5. mTOR Signaling Regulates Neuronal Phenotype Downstream
(A–E) Activation of mTOR signaling overcomes RTT neuronal phenotypes. Rhe
excitatory synaptic density (C and D), and smaller soma size (E) of MeCP2-KO h
(F–J) Activation of mTOR signaling ameliorates deficits caused by the inh
decreased mEPSC frequency (F and G), reduced excitatory synaptic density (H
campal neurons.
(K–O) Inactivation of mTOR signaling attenuates the effect of MeCP2 expressi
frequency (K and L), increased number of excitatory synapses (M and N), and en
(P–T) Inactivation of mTOR signaling attenuates the effects of miR-199a express
properties, such as enhanced mEPSC frequency (P and Q), increased number of
expressing neurons. Data are represented as mean ± SEM. *p < 0.05. The numb
quantification of neuronal soma size, n = 3 independent experiments; in each ex
(U and V) Schematic link between MeCP2 and mTOR signaling mediated by miRN
Drosha complex facilitates processing of the primary form of miR-199a to its prec
subjected to further processing to mature miR-199a by Dicer. The mature miR-
leading to reductions in the levels of their cognate proteins. Consequently, mTO
protein synthesis are eventually promoted. As a result, neuronal functions such as
deficient (RTT type) neurons, processing of pri-miR-199a to pre-miR-199a is imp
Decreased miR-199a cannot effectively suppress the expression of negative re
attenuation of mTOR signaling induces RTT neuronal phenotypes including dimi
Cell Repbeen determined, and we could not identify any common
sequence among mature sequences in the miRNA suggested
as MeCP2 targets in this study; we cannot rule out a possibility
that other factors, such as conformation and methylation state
of the outside regions, can play a critical role on regulating the
MeCP2 binding specificity.
Although it has been assumed that a reduction of mTOR
signal activity is involved in RTT pathogenesis, plausible molec-
ular link between MeCP2 and the mTOR signaling pathway
have been scant. Our findings clearly reveal a role for MeCP2
in the regulation of the mTOR signaling pathway as well as a
previously unknown miRNA-based mechanism by which
MeCP2 controls neuronal functions, which could clearly explain
RTT pathophysiology (Figures 5U and 5V). Most importantly,
we have demonstrated that genetic deletion of miR-199a-2
attenuates mTOR activity in the brain and recapitulates
numerous features of RTT patients and MeCP2 KO mice, sup-
porting the idea that the MeCP2/miR-199a/mTOR axis is
deeply involved in RTT phenotypes. Based on these findings,
we propose that dysregulation of the MeCP2/miR-199a/
mTOR axis contributes to the pathogenesis of neurodevelop-
mental disorders, and that an avenue for the development of
an effective therapeutic strategy against RTT is to control mol-
ecules involved in this pathway.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for additional details.
RNA Immunoprecipitation
Co-immunoprecipitation of RNAs with anti-MeCP2 antibody and their subse-
quent isolation were performed using a RiboCluster Profiler RIP-Assay kit
(MBL International Corporation) according to the manufacturer’s protocol.
Whole-cell lysates were sonicated and used for the RNA immunoprecipitation
assay. Rabbit immunoglobulin G (IgG) supplied by the manufacturer was used
as a control and the immunoprecipitated RNA was analyzed by qRT-PCR
using a TaqMan pri-microRNA assay kit (Applied Biosystems) with specific
primers.
Luciferase Assay
Hippocampal neurons were co-transfected with control (pLLX) or miR-199a
expression vector and pmirGLO-Pde4d, Sirt1, Hif1a-30 UTR-Nat orof MeCP2
b expression rescues the decreased mEPSC frequency (A and B), reduced
ippocampal neurons.
ibition of miR-199a-5p. Rheb expression restores abnormalities such as
and I), and smaller soma size (J) of miR-199a-5p inhibitor-expressing hippo-
on. Inhibition of mTOR signaling by rapamycin abrogates enhanced mEPSC
largement of soma area (O) of MeCP2-expressing neurons.
ion. Blocking of mTOR signaling by rapamycin abolished potentiated neuronal
excitatory synapses (R and S), and enlargement of soma area (T) of miR-199a-
er of neurons analyzed is shown under the bars. Scale bars, 5 mm. Regarding
periment, at least 100 neurons were assessed.
A biogenesis, explaining RTT neuronal phenotype U. In normal cells, MeCP2-
ursor form. The precursor miR-199a is translocated to the cytoplasm and then
199a-5p targets mTOR signaling inhibitors, such as Pde4d, Sirt1, and Hif1a,
R signal activity is upregulated, and downstream cellular processes including
excitatory synaptic transmission and cell growth are potentiated. (V) InMeCP2-
aired by MeCP2 deficiency, resulting in a reduced level of mature miR-199a.
gulators of mTOR signaling, so that mTOR signal activity is attenuated. This
nished excitatory synaptic transmission and cell growth.
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Figure 6. Loss of miR-199a-2 Recapitulates RTT Phenotypes
(A and B) Comparison of body size of WT, heterozygous (Het), and miR-199a-2 KO littermates.
(C) Comparison of brain size of WT, Het, and miR-199a-2 KO littermates.
(D) miR-199a-2 KO mice body weight is less than that of WT and Het littermates (measured from postnatal 3–6 weeks). Data are represented as mean ± SEM.
n = 3–5.
(E) Plots of the phenotypic scores of WT, Het, and miR-199a-2 KO littermates. Data are represented as mean ± SEM. n = 3–6.
(F) Representative immunohistological images of WT, Het, and miR-199a-2 KO hippocampi. Brain sections at 6 weeks were stained with anti-NeuN
(green) antibody and Hoechst 33258 (blue). Hippocampus size of miR-199a-2 KO is smaller than that of WT, but abnormal structural changes were not
observed.
(G) Representative immunohistological images of WT and miR-199a-2 KO cortices. Brain sections at 6 weeks were stained with anti-NeuN (green) antibody and
Hoechst 33258 (blue). Abnormal structural changes are not detected in miR-199a-2 KO brain.
(H) Representative immunohistological images of cortical layer II/III regions of WT and miR-199a-2 KO mice. Brain sections at 6 weeks were stained with anti-
NeuN (green) and Hoechst 33258 (blue). Decreased soma size of neurons and increased neuronal packing density were observed in miR-199a-2 KO mice.
(I) Quantification of neuronal soma size in (H). *p < 0.05 compared to WT; n = 9 sections (n = 3 brains of each genotype).
(J) Representative immunohistological images of hippocampus CA3 regions of WT and miR-199a-2 KO mice. Brain sections at 6 weeks were stained
with anti-NeuN (green) and Hoechst 33258 (blue). Decreased soma size of neurons and increased neuronal packing density are observed in miR-199a-2
KO mice.
(K) Quantification of neuronal soma size in (J). *p < 0.05 compared to WT; n = 9 sections (n = 3 brains from each genotype).
1898 Cell Reports 12, 1887–1901, September 22, 2015 ª2015 The Authors
Figure 7. Loss of miR-199a-2 Results in a Decreased mTOR Activity in the Brain
(A) Representative immunohistological images of WT and miR-199a-2 KO cortices. Brain sections at 6 weeks were stained with anti-NeuN (green) and p-S6 (red)
antibodies. mTOR activity in the cortex was markedly reduced in miR-199a-2 KO mice.
(B) pS6-positive neurons in (A) were quantified. *p < 0.05 compared to WT; n = 9 sections (n = 3 brains from each genotype).
(C) Representative immunohistological images of hippocampus CA3 regions of WT and miR-199a-2 KO mice. Brain sections at 6 weeks were stained with anti-
NeuN (green) and p-S6 (red) antibodies. mTOR activity in the hippocampus dramatically reduced in miR-199a-2 KO mice.
(D) pS6-positive neurons in (C) were quantified. *p < 0.05 compared to WT; n = 9 sections (n = 3 brains from each genotype). Nuclei are visualized by Hoechst
staining (A and C, insets).pmirGLO-Pde4d, Sirt1, Hif1a-30 UTR-Mut using Lipofectamine 2000. After
transfection, the cells were incubated for 6 days and lysed with reporter lysis
buffer. Luciferase activity of the lysates was measured with the Dual-Glo
Luciferase Assay System (Promega) according to the manufacturer’s
protocol. Firefly luciferase activities were determined by three independent
transfections and normalized by comparison with the Renilla luciferase activ-
ities of the internal control.
Scoring of Symptoms
Neurological symptoms of mice were scored as previously described (Guy
et al., 2007).
Statistical Analysis
The results presented are the average of at least three experiments, each per-
formed in triplicate, with SEs. Statistical analyses were performed by one-way
ANOVA, followed by Tukey’s or Bonferroni multiple comparison tests, or by
Student’s t test as appropriate, using Prism 5 (GraphPad Software). Probabil-
ities of p < 0.05 were considered significant.Cell RepACCESSION NUMBERS
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